December 2025 Interview with Michael Breen, Executive Chairman and CEO of GT Biopharma December 15, 2025
Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA) November 10, 2022
H.C. Wainwright 24th Annual Global Investment Conference, September 12 – 14, 2022 Webcast – Replay September 15, 2022
ESMO: B7H3-Targeted Tri-specific Killer Engagers deliver IL-15 to NK cells but not T cells, and specifically targets solid tumors as a pan-tumor antigen strategy mediated through NK cells September 12, 2022
